Amwell's Digital Mental Health Solution Shows Significant Results in Major Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
- Large-Scale Study: The independently funded randomized trial by the National Institute of Mental Health involved 6,205 clinical or high-risk students across 26 U.S. colleges, making it one of the largest independent studies of its kind, showcasing Amwell's significant impact in mental health.
- Significant Engagement Rates: Students using SilverCloud had a participation rate of 74.4%, compared to just 30.2% for traditional behavioral health solutions, indicating the superior ability of digital mental health solutions to engage users and potentially drive broader adoption.
- Improvement in Mental Health: Those receiving digital behavioral healthcare showed a 4.3%, 4.9%, and 3.8% lower prevalence of mental disorders at six weeks, six months, and two years respectively, demonstrating the effectiveness of early intervention, particularly among financially stressed student populations.
- Economic Value Potential: The study suggests that the 3.8% reduction in mental disorder prevalence over two years could translate into approximately $1.18 million in avoided mental health-related costs within the study sample, highlighting the economic value and strategic significance of digital mental health programs in higher education and health plans.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMWL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMWL
Wall Street analysts forecast AMWL stock price to fall
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 8.840
Low
6.00
Averages
6.00
High
6.00
Current: 8.840
Low
6.00
Averages
6.00
High
6.00
About AMWL
American Well Corporation operates a hybrid care, delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver access to more affordable quality care. It offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. The Amwell Converge platform offers data architecture and video capabilities, flexibility and scalability, as well as a user experience focused on the needs of patients, members and providers. For health systems, its enterprise platform enables provider-to-provider virtual care for use cases ranging from stroke to virtual nursing and e-sitting. Its Amwell Carepoint devices enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings, helping to address personnel shortages and access limitations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon Appoints New Head for Healthcare Business
- New Leadership: Amazon has appointed Dr. Roy Schoenberg, 58, co-founder of telehealth company American Well, to lead its healthcare business starting July 1, which is expected to drive further growth in Amazon's healthcare sector.
- Leadership Transition: Current healthcare head Neil Lindsay will leave by year-end after nearly five years, and his lack of healthcare background may impact the strategic direction of Amazon's healthcare initiatives moving forward.
- Business Growth: Amazon's healthcare segment includes One Medical clinics and mail-order prescriptions, and while the company does not disclose specific results, it has indicated that this is one of its fastest-growing businesses, highlighting significant market potential.
- Market Reaction: Amazon's shares rose 2.5% to $271.85, while Amwell's shares increased by 4.2% to $8.84, reflecting investor confidence in the new leadership and optimism regarding the future of the healthcare business.
See More
Amwell's Digital Mental Health Solution Shows Significant Results in Major Study
- Large-Scale Study: The independently funded randomized trial by the National Institute of Mental Health involved 6,205 clinical or high-risk students across 26 U.S. colleges, making it one of the largest independent studies of its kind, showcasing Amwell's significant impact in mental health.
- Significant Engagement Rates: Students using SilverCloud had a participation rate of 74.4%, compared to just 30.2% for traditional behavioral health solutions, indicating the superior ability of digital mental health solutions to engage users and potentially drive broader adoption.
- Improvement in Mental Health: Those receiving digital behavioral healthcare showed a 4.3%, 4.9%, and 3.8% lower prevalence of mental disorders at six weeks, six months, and two years respectively, demonstrating the effectiveness of early intervention, particularly among financially stressed student populations.
- Economic Value Potential: The study suggests that the 3.8% reduction in mental disorder prevalence over two years could translate into approximately $1.18 million in avoided mental health-related costs within the study sample, highlighting the economic value and strategic significance of digital mental health programs in higher education and health plans.
See More
American Well Q1 2026 Earnings Call Insights Highlighting Growth and Profitability Path
- Strong Financial Performance: American Well reported total revenue of $54.9 million in Q1 2026, with a gross profit of $28 million and a gross margin of 51%, reflecting robust visit volumes in urgent care and clinical programs while maintaining cost discipline, thereby enhancing its competitive position in the market.
- Improved Adjusted EBITDA Outlook: The company now expects its full-year adjusted EBITDA loss for 2026 to narrow to between $16 million and $12 million, down from the previous forecast of $24 million to $18 million, indicating increased management confidence in profitability trajectory.
- Healthy Cash Flow Position: As of the end of Q1, American Well had $179 million in cash and investments with no debt, with management outlining a clear path to cash flow breakeven by Q4 2026, which bolsters investor confidence in the company's financial stability.
- Positive Forward Guidance: The company anticipates Q2 2026 revenue in the range of $48 million to $52 million, suggesting strong future growth potential driven by ongoing customer demand and market expansion, particularly in telehealth and behavioral health sectors.
See More
American Well Corporation Shares Surge 13.3% Amid Strong Q4 Outlook
- Significant Price Surge: American Well Corporation (AMWL) shares rallied 13.3% in the last trading session to close at $6.24, with notable trading volume indicating strong investor optimism regarding the company's future performance.
- Strong Financial Performance: The company reported fourth-quarter sales of $55.3 million, surpassing the Zacks Consensus Estimate by 5.3%, highlighting its robust growth potential in the digital healthcare sector, which may attract more investor interest.
- Future Expectations: Although a quarterly loss of $0.77 per share is anticipated, reflecting a year-over-year increase of 55.5%, revenues are expected to decline by 24.8% to $50.25 million, indicating cautious market sentiment regarding the company's future profitability.
- Market Trend Monitoring: Despite the consensus EPS estimate remaining unchanged over the past 30 days, the stock's upward movement may be linked to growing investor enthusiasm for AI-driven digital healthcare platforms, making AMWL's future performance worth monitoring.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
Amwell Grants 61,559 RSUs to New Employee as Inducement
- Employee Inducement Plan: On February 18, 2026, Amwell granted 61,559 restricted stock units (RSUs) to a new employee as a significant inducement for employment, demonstrating the company's commitment to attracting and retaining talent.
- Vesting Schedule: The RSUs will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal pro-rata increments every three months over three years, ensuring employee stability and long-term commitment during this period.
- Compliance Assurance: This grant was approved by Amwell's Compensation Committee and made in reliance on the employment inducement exemption under NYSE's Listed Company Manual Rule 303A.08, ensuring the company operates within compliance frameworks.
- Platform Advantage: Amwell offers a comprehensive technology-enabled healthcare platform aimed at providing patients with more convenient, affordable, and effective care, and as demand for online healthcare increases, the company's competitive position and influence in the market continue to grow.
See More
Amazon Appoints New Head for Healthcare Business
- New Leadership: Amazon has appointed Dr. Roy Schoenberg, 58, co-founder of telehealth company American Well, to lead its healthcare business starting July 1, which is expected to drive further growth in Amazon's healthcare sector.
- Leadership Transition: Current healthcare head Neil Lindsay will leave by year-end after nearly five years, and his lack of healthcare background may impact the strategic direction of Amazon's healthcare initiatives moving forward.
- Business Growth: Amazon's healthcare segment includes One Medical clinics and mail-order prescriptions, and while the company does not disclose specific results, it has indicated that this is one of its fastest-growing businesses, highlighting significant market potential.
- Market Reaction: Amazon's shares rose 2.5% to $271.85, while Amwell's shares increased by 4.2% to $8.84, reflecting investor confidence in the new leadership and optimism regarding the future of the healthcare business.
See More
Amwell's Digital Mental Health Solution Shows Significant Results in Major Study
- Large-Scale Study: The independently funded randomized trial by the National Institute of Mental Health involved 6,205 clinical or high-risk students across 26 U.S. colleges, making it one of the largest independent studies of its kind, showcasing Amwell's significant impact in mental health.
- Significant Engagement Rates: Students using SilverCloud had a participation rate of 74.4%, compared to just 30.2% for traditional behavioral health solutions, indicating the superior ability of digital mental health solutions to engage users and potentially drive broader adoption.
- Improvement in Mental Health: Those receiving digital behavioral healthcare showed a 4.3%, 4.9%, and 3.8% lower prevalence of mental disorders at six weeks, six months, and two years respectively, demonstrating the effectiveness of early intervention, particularly among financially stressed student populations.
- Economic Value Potential: The study suggests that the 3.8% reduction in mental disorder prevalence over two years could translate into approximately $1.18 million in avoided mental health-related costs within the study sample, highlighting the economic value and strategic significance of digital mental health programs in higher education and health plans.
See More
American Well Q1 2026 Earnings Call Insights Highlighting Growth and Profitability Path
- Strong Financial Performance: American Well reported total revenue of $54.9 million in Q1 2026, with a gross profit of $28 million and a gross margin of 51%, reflecting robust visit volumes in urgent care and clinical programs while maintaining cost discipline, thereby enhancing its competitive position in the market.
- Improved Adjusted EBITDA Outlook: The company now expects its full-year adjusted EBITDA loss for 2026 to narrow to between $16 million and $12 million, down from the previous forecast of $24 million to $18 million, indicating increased management confidence in profitability trajectory.
- Healthy Cash Flow Position: As of the end of Q1, American Well had $179 million in cash and investments with no debt, with management outlining a clear path to cash flow breakeven by Q4 2026, which bolsters investor confidence in the company's financial stability.
- Positive Forward Guidance: The company anticipates Q2 2026 revenue in the range of $48 million to $52 million, suggesting strong future growth potential driven by ongoing customer demand and market expansion, particularly in telehealth and behavioral health sectors.
See More
American Well Corporation Shares Surge 13.3% Amid Strong Q4 Outlook
- Significant Price Surge: American Well Corporation (AMWL) shares rallied 13.3% in the last trading session to close at $6.24, with notable trading volume indicating strong investor optimism regarding the company's future performance.
- Strong Financial Performance: The company reported fourth-quarter sales of $55.3 million, surpassing the Zacks Consensus Estimate by 5.3%, highlighting its robust growth potential in the digital healthcare sector, which may attract more investor interest.
- Future Expectations: Although a quarterly loss of $0.77 per share is anticipated, reflecting a year-over-year increase of 55.5%, revenues are expected to decline by 24.8% to $50.25 million, indicating cautious market sentiment regarding the company's future profitability.
- Market Trend Monitoring: Despite the consensus EPS estimate remaining unchanged over the past 30 days, the stock's upward movement may be linked to growing investor enthusiasm for AI-driven digital healthcare platforms, making AMWL's future performance worth monitoring.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
Amwell Grants 61,559 RSUs to New Employee as Inducement
- Employee Inducement Plan: On February 18, 2026, Amwell granted 61,559 restricted stock units (RSUs) to a new employee as a significant inducement for employment, demonstrating the company's commitment to attracting and retaining talent.
- Vesting Schedule: The RSUs will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal pro-rata increments every three months over three years, ensuring employee stability and long-term commitment during this period.
- Compliance Assurance: This grant was approved by Amwell's Compensation Committee and made in reliance on the employment inducement exemption under NYSE's Listed Company Manual Rule 303A.08, ensuring the company operates within compliance frameworks.
- Platform Advantage: Amwell offers a comprehensive technology-enabled healthcare platform aimed at providing patients with more convenient, affordable, and effective care, and as demand for online healthcare increases, the company's competitive position and influence in the market continue to grow.
See More
